দেশ: অস্ট্রেলিয়া
ভাষা: ইংরেজি
সূত্র: Department of Health (Therapeutic Goods Administration)
normal immunoglobulin, Quantity: 160 mg/mL
CSL Behring Australia Pty Ltd
normal immunoglobulin
Injection, solution
Excipient Ingredients: glycine
Intramuscular
5 mL
(S1) This Schedule is intentionally blank
Normal Immunoglobulin-VF is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. It may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. In susceptible contacts of hepatitis A, measles and poliomyelitis, Normal Immunoglobulin-VF may be of value in preventing or modifying the disease. In general, the earlier in the incubation period of these diseases Normal Immunoglobulin-VF is given, the greater its effectiveness. Hepatitis A Routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals: - Household contacts of an index case, who have not already had hepatitis A or have no serological evidence of immunity to the virus. - Common source exposures. When a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of Normal Immunoglobulin-VF should be considered for all those exposed to the source. - Institutional contacts. - Staff in institutions where hepatitis is endemic. Routine prophylaxis is not recommended for school, office, factory or hospital contacts.
Visual Identification: Colourless, clear to opalescent solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Licence status A
2006-03-01